Jan 28 (Reuters) - Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Our Standards: The Thomson Reuters Trust Principles.
